Gsa Capital Partners LLP Nuvation Bio Inc. Transaction History

Gsa Capital Partners LLP

$1.2 Billion
Q3 2025

A detailed history of Gsa Capital Partners LLP transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 1,035,192 shares of NUVB stock, worth $5.03 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares

1,035,192

Previous 1,627,122 36.38%

Holding current value

$5.03 Million

Previous $3.17 Million 20.71%

% of portfolio

0.32%

Previous 0.22%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	SELL	$1.94 - $3.9 $1.15 Million - $2.31 Million	-591,930 Reduced 36.38%	1,035,192 $3.83 Million
Q2 2025 Jul 22, 2025	BUY	$1.66 - $2.53 $1.6 Million - $2.44 Million	966,070 Added 146.14%	1,627,122 $3.17 Million
Q1 2025 May 08, 2025	BUY	$1.76 - $3.25 $737,086 - $1.36 Million	418,799 Added 172.88%	661,052 $1.16 Million
Q4 2024 Feb 07, 2025	BUY	$2.01 - $3.01 $336,315 - $503,636	167,321 Added 223.3%	242,253 $644,000
Q3 2024 Nov 05, 2024	BUY	$2.3 - $3.83 $172,343 - $286,989	74,932 New	74,932 $172,000

Q4 2023 Feb 16, 2024	SELL	$0.96 - $1.53 $180,018 - $286,904	-187,519 Reduced 81.43%	42,776 $64,000
Q3 2023 Nov 15, 2023	SELL	$1.26 - $2.1 $58,451 - $97,419	-46,390 Reduced 16.77%	230,295 $308,000
Q2 2023 Aug 14, 2023	SELL	$1.56 - $1.84 $65,331 - $77,057	-41,879 Reduced 13.15%	276,685 $498,000
Q1 2023 May 12, 2023	BUY	$1.6 - $2.48 $113,636 - $176,137	71,023 Added 28.69%	318,564 $528,000
Q4 2022 Feb 13, 2023	BUY	$1.68 - $2.5 $82,595 - $122,910	49,164 Added 24.78%	247,541 $475,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $47,454 - $661,085	163,635 Added 471.0%	198,377 $444,000
Q2 2022 Aug 09, 2022	BUY	$3.24 - $5.85 $112,564 - $203,240	34,742 New	34,742 $113,000

Others Institutions Holding NUVB

# of Institutions

218

Shares Held

165M

Call Options Held

1.99M

Put Options Held

660K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $1.06B
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account

Gsa Capital Partners LLP Nuvation Bio Inc. Transaction History